Electrochemotherapy in vulvar cancer: a systematic review

C. Certelli, G. Garganese, S. Fragomeni, L. Tagliaferri, I. Paris, M. A. Gambacorta, G. Scambia, G. Corrado

1Dipartimento Scienze della Salute della Donna, del Bambino, e di Sanità Pubblica, Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Gemelli ART (Advanced Radiation Therapy), Intervventional Oncology Center (IOC) Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
3Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Gemelli ART (Advanced Radiation Therapy), Intervventional Oncology Center (IOC) Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
4Dipartimento Scienze della Salute della Donna, del Bambino, e di Sanità Pubblica, Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
5Gynecology and Breast Care Center, Mater Olbia Hospital, Olbia, Italy

ABSTRACT

There are some problems about the optimal treatment modality of vulvar cancer (VC): unfeasible surgery in elderly women with several comorbidities and the absence of treatments applicable in recurrent disease. For these reasons, Electrochemotherapy (ECT) may have an important role in the management of these patients. The aim of this systematic review is to evaluate ECT in VC in terms of clinical response, adverse events and quality of life (QoL). We conducted a search on the electronic database PubMed/MEDLINE. All the studies in English language published from 2006 and August 2019 were considered eligible. The 4 studies included in the systematic review reported an overall objective response rate (complete and partial response) was 74.3%. No treatment-related serious adverse events were reported in any of the studies. An improvement in the QoL was reported. In conclusion, ECT is a simple, quick to perform, less invasive and repeatable procedure, which has shown a positive clinical response, a reduction in symptoms and an improvement in QoL. Since the survival for advanced and metastatic diseases has been, fortunately, increased, it is also important to focus our efforts on the QoL and on the local control of the disease.

Corresponding Author: Camilla Certelli certelli.camilla@gmail.com

Key words: electrochemotherapy; vulvar cancer; palliative therapies
INTRODUCTION

Electrochemotherapy (ECT) combines electroporation and chemotherapeutic drugs in order to destroy or reduce in size different kinds of lesions. The electroporation improves drugs delivery by increasing the cell membrane permeability and makes chemotherapy more effective (1). There are three mechanisms of action of ECT (2): first, the cytotoxic effect of chemotherapy; second, an anti-vascular effect with a vasoconstriction phase followed by vascular disruption (3,4); third, an immune stimulation (5,6). The applications of ECT have been extended in recent years. ECT has been used in the treatment of metastatic melanoma in conjunction with standard chemotherapy in order to obtain a better local control of the disease (7,8). Two recent multicentric studies reported 71% of positive response to the ECT treatment in breast cancer patients (9, 10). In head and neck cancers, ECT may be a valid less invasive option to preserve physiological functions (11). Furthermore, ECT showed positive results in non-melanoma skin cancers and soft tissues sarcomas and even in non-cancer skin lesions (2). More recently, promising results have been reported in vulvar cancer treatment. Vulvar cancer (VC) accounts for 5% of all gynaecologic malignancies (12) and there are some problems about the optimal treatment modality. Indeed, radical surgery often requires the need for plastic reconstruction, by different techniques (13, 14), and frequently involves a high post-operative burden (15). On the one hand, since vulvar cancer mainly affects elderly women, comorbidities often make surgery unfeasible, whereas on the other hand, even when surgery, chemotherapy and/or radiotherapy are applicable, in the different settings up to the palliative care (16, 17, 18), recurrences are not rare and to provide additional care remains a real challenge. For these reasons, ECT may have an important role in the management of these patients. The aim of this systematic review is to evaluate ECT in VC in terms of clinical response, adverse events and quality of life (QoL).

MATERIALS AND METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used as a guide for this systematic review (19). The Population, Intervention, Comparator and Outcomes (PICO) framework was used to formulate a search question in the following way: P: vulvar cancer; I: electrochemotherapy; O: clinical response. The “C” was not included because of the absence of a comparator. Indeed, ECT is emerging in more recent years and it is used as a palliative treatment in the majority of the cases. For this reason, comparing ECT with other less effective or none treatment would be unethical. Although the first objective of this systematic review was the evaluation of the clinical response, we added two secondary endpoints of our research: the evaluation of the adverse events and the QoL. We conducted a search on the electronic database PubMed/MEDLINE, by using the following terms: “electrochemotherapy” OR “ECT” AND “vulvar cancer”. All the studies in English language published from the publication of the Standard Operating Procedures in 2006 (20) and August 2019 were considered eligible. The inclusion criteria were: diagnosis of VC, studies in which at least one of the three endpoints (clinical response, adverse events and QoL) was evaluated, studies in which the ECT was used as adjuvant or exclusive treatment. Abstracts, communications, comments, reviews and non-English language studies were excluded. Since this study is a systematic review of the literature based on previous published articles, no ethical approval or patient consent are required.

RESULTS

The search yielded a total of 8 studies after duplicates were removed (Figure 1). We excluded 4 studies because of the following reasons: published before 2006, reviews or ECT was not used as exclusive or adjuvant treatment. Thus, 4 studies were included in the systematic review. All the studies included were prospective and the total number of patients was 105. Patients’ and studies characteristics are shown in Table I. The median age ranged from 68 to 85 years. Although the most common histology of VC was squamous cell carcinoma, there were two studies that included Paget diseases and one vulvar melanoma. Up to 40% of the patients in each
**Table I. Patients’ and studies characteristics.**

<table>
<thead>
<tr>
<th>Author</th>
<th>Type of study</th>
<th>Patients</th>
<th>Age</th>
<th>FIGO stage</th>
<th>Histology</th>
<th>Previous treatments</th>
<th>Multiple lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perrone et al.</td>
<td>prospective</td>
<td>9</td>
<td>84 ± 3.9</td>
<td>II: 2 (22%) III: 3 (33%) IV: 4 (45%) 0</td>
<td>SCC</td>
<td>8 (88.9%)</td>
<td>2 (25%)</td>
</tr>
<tr>
<td>Perrone et al.</td>
<td>prospective</td>
<td>25</td>
<td>85 (66-96)</td>
<td>I: 13 (52%) II: 8 (32%) III: 3 (12%) I: 1 (4%)</td>
<td>SCC</td>
<td>21 (84%)</td>
<td>8 (32%)</td>
</tr>
<tr>
<td>Perrone et al.</td>
<td>prospective</td>
<td>10</td>
<td>68 (59-84)</td>
<td>I: 4 (40%) II: 4 (40%) III: 1 (10%) 0</td>
<td>SCC 1 PD</td>
<td>8 (80%)</td>
<td>4 (40%)</td>
</tr>
<tr>
<td>Perrone et al.</td>
<td>prospective</td>
<td>61</td>
<td>79 (39-85)</td>
<td>I: 24 (39%) II: 3 (4.9%) III: 7 (11.5%) 2 (3.3%)</td>
<td>SCC 3 PD 1 Melanoma</td>
<td>45 (73.8%)</td>
<td>24 (39.3%)</td>
</tr>
</tbody>
</table>

Data are shown as median (range) or mean ± SD and n (%). SCC: squamous cell carcinoma. PD: Paget Disease

study showed multiple lesions at the first pre-treatment examination. The primary tumour FIGO stage was I in the majority of the patients (41%), whereas only 3 patients were in FIGO stage IV. The majority of the patients (78%) underwent previous treatments before ECT, which were surgery in most of the cases with or without adjuvant therapies such as chemotherapy and/or radiotherapy. Data about ECT administration and clinical response are shown in table II. All the studies used intravenous Bleomycin as chemotherapeutic drug. In most of the patients general anaesthesia was used and the duration of the procedure was 20-28 min. The median hospital stays after ECT ranged from 1 to 3 days. For the response evaluation, two studies used the World Health Organization (WHO) criteria, whereas the other two studies used the Response Evaluation Criteria in Solid Tumours (RECIST) and the time of the response evaluation was in most of the studies 1 month. As regards the response rate, the 4 studies reported the following results: 49 (46.7%) complete response (CR), 29 (27.6%) partial response (PR), 12 (11.4%) stable disease (SD) and 8 (7.6%) progressive disease (PD). The overall objective response rate (CR and PR) was 74.3%. No differences in the clinical response emerged between previously treated and non-treated patients (21) and, in the same way, no variations in the response rate emerged according to the number or diameter of the lesions (21,22).

Furthermore, Perrone et al. showed that age, BMI, FIGO stage, site and histology did not influence the response to the treatment (22). No treatment-related serious adverse events were reported in any of the studies. Some studies reported minor local side effects such as minimal blood loss, oedema, erythema, hyperpigmentation, skin ulceration and mild pain (table II) (21,22,23).

Only three studies evaluated the QoL and all of them reported a significant QoL improvement after treatment (23,24).

In particular, they showed a reduction in bleeding, odour, urinary discomfort and pain (23,24). Perrone et al. reported a symptomatic response rate of 78% and they did not find differences in symptom-free survival according to previous treatments or tumor diameter (21).

In the end, with a follow-up of 6-12 months the overall survival exceeded 50% (table II).
### Table II. ECT, clinical response and adverse events

<table>
<thead>
<tr>
<th>Author</th>
<th>CT</th>
<th>Administration</th>
<th>Anesthesia</th>
<th>Procedure time (min)</th>
<th>H stay (days)</th>
<th>Response</th>
<th>Response eval. criteria</th>
<th>Eval. time (mo)</th>
<th>Adverse events</th>
<th>Qol</th>
<th>Follow up (mo)</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perrone et al. 2013</td>
<td>BLM</td>
<td>IV</td>
<td>general</td>
<td>20 +/- 4 min</td>
<td>1</td>
<td>CR 5</td>
<td>WHO 1</td>
<td>9.1 ± 3.5</td>
<td>-Minimal blood loss-oedema</td>
<td>yes</td>
<td>9.1 ± 3.5</td>
<td>50%</td>
</tr>
<tr>
<td>Perrone et al. 2015</td>
<td>BLM</td>
<td>IV</td>
<td>Local + sedation</td>
<td>28 min</td>
<td>1</td>
<td>PR 13</td>
<td>RECIST 1</td>
<td>7 (1-27)</td>
<td>-Minimal blood loss-oedema</td>
<td>yes</td>
<td>7 (1-27)</td>
<td>-</td>
</tr>
<tr>
<td>Pellegrino et al. 2016</td>
<td>BLM</td>
<td>IV</td>
<td>-</td>
<td>20 (10-20)</td>
<td>-</td>
<td>NR/SD 2</td>
<td>WHO 1</td>
<td>yes</td>
<td>none</td>
<td>yes</td>
<td>12</td>
<td>60%</td>
</tr>
<tr>
<td>Perrone et al. 2019</td>
<td>BLM</td>
<td>IV</td>
<td>48 (79%) general, 13 (21%) local</td>
<td>48 (79%) general, 13 (21%) local</td>
<td>3 (0-8)</td>
<td>CR 29</td>
<td>RECIST 2</td>
<td>6</td>
<td>-Erythema 20% -hyperpigmentation 6% -skin ulceration 1% -mild pain 24%</td>
<td>no</td>
<td>6</td>
<td>72%</td>
</tr>
</tbody>
</table>

Data are shown as median (range) or mean ± SD and n (%). ECT: electrochemotherapy. CT: chemotherapy. BLM: bleomycin. CR: complete response. PR: partial response. NR: no response. SD: stable disease. PD: progressive disease. IV: intravenous.
DISCUSSION

Modern oncology is increasingly characterized by minimally invasive therapeutic proposals (Interventional Oncology) (25,26). Especially the elderly (27,28) but also patients with comorbidity (29) can benefit from these types of procedures. ECT is part of this and it has demonstrated to be a valid option in the management of VC, showing a positive clinical response and an improvement of the QoL without serious adverse events. The studies we considered in our systematic review were quite homogeneous. This is related to two reasons: on the one hand, the Standard Operating Procedures publication in 2006 and their update in 2018 (30) created a standardization of the procedure; on the other hand, the majority of the studies were conducted by the same institutions. Since the possibility of a duplication of the patients could not be avoided, it was not possible to add a meta-analysis, which is one of the limits of our research. Furthermore, the num-
Electrochemotherapy in vulvar cancer

C. Certelli et al.

The number of studies on ECT in VC is very low, because of the recent application of ECT in these kind of cancers. ECT in VC showed a CR rate of 46.7% and, although the response evaluation criteria were a bit different between the studies, the CR definition is the same. In a recent meta-analysis for the evaluation of ECT in different kind of tumors (VC not included), Morley et al. reported similar results, despite a higher objective response rate (82.2%) (31). Although some studies have reported a better response rate for tumors smaller than 3cm (31) and even the Standard Operating Procedures have suggested the possibility of different chemotherapy administration according to the tumor diameter (30), none of the studies in our systematic review found differences in the response rate (21,22). Furthermore, ECT response seemed not to be affected by any of the parameters considered in the studies (21,22). An interesting result was the absence of influence in the response rate when a previous treatment was administered (21), whereas some studies have found that treatment-naïve tumours responded better, probably because of a worse effect of ECT after radiotherapy, due to the reduction of the blood flow because of the fibrosis (31). As regards the survival outcomes, it is difficult to get conclusions because of the lack of homogeneity among the patients. Indeed, different previous treatments or the use of co-interventions may affect the survival outcomes. However, considering that ECT was more often used as a palliative treatment or when no other treatments were available, the survival outcomes showed by our research may be promising. The most common adverse events reported by our research were local: minimal blood loss, oedema, erythema, hyperpigmentation, skin ulceration and mild pain. Morley et al. showed minimal serious adverse events, whereas the most common were mild, post-procedural nausea and dizziness (31). Although ECT is associated with a 6% incidence of G3 toxicity, this rate is similar to other skin-directed therapies (2). All the studies we considered in our systematic review agreed with the fact that ECT is associated with an improvement in QoL. In a cohort of 52 patients, Campana et al. reported positive results of ECT in melanomas on local disease-related complaints such as wound healing, bleeding or pain and on activity of daily life (32). In head and neck cancer, which is a site where maintaining physiological functions is very important, ECT showed an improvement in physical functioning, role functioning and fatigue and pain reduction (33). Further applications of ECT include extra cycles of ECT and the use of this procedure as neoadjuvant treatment. First, few data exist on additional cycles of ECT (31). In VC, in two studies there were more than one ECT administration (21,24). Perrone et al. performed a second ECT cycle in a limited number of patients (20%) and they reported: CR 40%, SD 20% and PD 40% (21). Pellegrino et al. performed even more than two cycles of ECT and no complications occurred (24). Indeed, ECT have demonstrated to be a repeatable treatment, without increasing the adverse events rate and with similar results in clinical response. Second, acceptable aesthetic and functional results are often difficult to obtain in VC and, especially, in recurrent disease and extensive reconstructions are required (34,35). For this reason, ECT has been recently proposed as neo-adjuvant treatment, in order to reduce the tumor size and make the surgery less invasive and disabling. However, only one study evaluated this new application in a small group of patients with a positive objective response rate (77.8%) (36) and further data are needed. The few data we have on extra cycles of ECT seem to suggest that it maintains its safety and efficacy. For this reason, it can be able to obtain and/or maintain the tumour clinical response through repeated cycles of ECT (31). Furthermore, since the radiotherapy and surgery are often not repeatable and the chemotherapy role is debated in VC, according to the few but promising results of ECT as neo-adjuvant treatment, ECT may have also a theoretical role as an integrated procedure to standard surgical treatment techniques, although further specific studies are needed. Large-database using multi-centric system could help to develop predictive models (37) and decision support.
tools that could be implemented in the clinical practice for improving the multidisciplinary discussing and for identifying the patients that may benefit by electrochemotherapy (38-40). In conclusion, ECT has demonstrated advantages in terms of reduction of hospital stay and costs. Furthermore, it is an easy, quick to perform, less invasive and repeatable procedure, which has shown a positive clinical response, a reduction in symptoms and an improvement in QoL. However, few studies are present on VC and further data are needed.

Since the survival for advanced and metastatic diseases has been, fortunately, increased, it is also important to focus our efforts on the QoL and on the local control of the disease.
REFERENCES

(1) Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumor coverage by sufficiently high local electric field for effective chemotherapy. Eur J Cancer Suppl 2006; 4:45-51.
(20) Mir LM, Gehr J, Sersa G, Collins CG, Garbay JR, Billard V et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric...
2020, 32: N.1

Electrochemotherapy in vulvar cancer

pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes.  

EJC Supplements 2006;4: 14-25.


